Companies Cryptocurrencies
Ocugen Inc
Ocugen Inc
Exchange: NasdaqGS
IPO Date: 03/12/2014
CEO: Dr. Shankar Musunuri
Biotechnology Healthcare 🔗
  • OCGN
  • 2.735
  • 592307968
    market cap
  • -0.09500003
If you bought

shares of Ocugen Inc (OCGN) on
You would have made
Old Price $12 Current Price $12

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 49 full-time employees. The firm offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The firm is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The firm is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Address: 5 Great Valley Pkwy Ste 160 Malvern PENNSYLVANIA 19355

Stay updated.